Areas of Cartilaginous and Osseous Metaplasia After Experimental Myocardial Infarction in Rats

Manole, Catalin G.; Marinescu, Bogdan Gabriel; Marta, Daciana; Nicolescu, Mihnea Ioan

doi:10.1002/ar.24010

Cited by 9 publications

(10 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Vascular cartilaginous/osseous metaplasia, which is often associated with the presence of arterial chondrocytes that express type II collagen, is known to be part of the progression of mineralization or atherosclerotic lesion ( Fitzpatrick et al, 2003 ; Nguyen et al, 2012 ). It also provides evidence of cardiac extracellular matrix remodeling for post-infarcted heart and may constitute a supplemental factor for heart failure when it calcifies ( Manole et al, 2019 ; Carreon et al, 2020 ). Cartilaginous metaplasia is considered a potential great risk for arterial wall calcification associated with the atherosclerotic plaque ( Qiao et al, 1995 ).…”

Section: Discussionmentioning

confidence: 99%

Therapeutic Potentials of Selected Antihypertensive Agents and Their Fixed-Dose Combinations Against Trastuzumab-Mediated Cardiotoxicity

et al. 2021

View full text Add to dashboard Cite

Trastuzumab (TZM) is useful in the clinical management of HER2-positive metastatic breast, gastric, and colorectal carcinoma but has been limited by its off-target cardiotoxicity. This study investigates the therapeutic potentials of 0.25 mg/kg/day amlodipine, 0.035 mg/kg/day lisinopril, 5 mg/kg/day valsartan, and their fixed-dose combinations in TZM-intoxicated Wistar rats that were randomly allotted into 10 groups of 6 rats for each group. Group I rats were treated with 10 ml/kg/day sterile water orally and 1 ml/kg/day sterile water intraperitoneally; Groups II, III, and IV rats were orally gavaged with 5 mg/kg/day valsartan and 1 ml/kg/day sterile water intraperitoneally, 0.25 mg/kg/day amlodipine and 1 ml/kg/day sterile water via the intraperitoneal route, 0.035 mg/kg/day lisinopril and 1 ml/kg/day sterile water administered intraperitoneally, respectively. Group V rats were orally treated with 10 ml/kg/day of sterile water prior to intraperitoneal administration of 2.25 mg/kg/day of TZM. Groups VI–VIII rats were equally pretreated with 5 mg/kg/day valsartan, 0.25 mg/kg/day amlodipine, and 0.035 mg/kg/day lisinopril before intraperitoneal 2.25 mg/kg/day TZM treatment, respectively; Groups IX and X rats were orally pretreated with the fixed-dose combinations of 0.25 mg/kg/day amlodipine +0.035 mg/kg/day lisinopril and 5 mg/kg/day valsartan +0.035 mg/kg/day lisinopril, respectively, before TZM treatment. Cardiac injury and tissue oxidative stress markers, complete lipids profile, histopathological, and immunohistochemical assays were the evaluating endpoints. Results showed that repeated TZM treatments caused profound increases in the serum TG and VLDL-c levels, serum cTnI and LDH levels, and cardiac tissue caspase-3 and -9 levels but decreased BCL-2 expression. TZM also profoundly attenuated CAT, SOD, GST and GPx activities, and increased MDA levels in the treated tissues. In addition, TZM cardiotoxicity was characterized by marked vascular and cardiomyocyte congestion and coronary artery microthrombi formation. However, the altered biochemical, histopathological, and immunohistochemical changes were reversed with amlodipine, lisinopril, valsartan, and fixed-dose combinations, although fixed-dose valsartan/lisinopril combination was further associated with hyperlipidemia and increased AI and CRI values and coronary artery cartilaginous metaplasia. Thus, the promising therapeutic potentials of amlodipine, lisinopril, valsartan and their fixed-dose combinations in the management of TZM cardiotoxicity, majorly mediated via antiapoptotic and oxidative stress inhibition mechanisms were unveiled through this study.

show abstract

Section: Discussionmentioning

confidence: 99%

Therapeutic Potentials of Selected Antihypertensive Agents and Their Fixed-Dose Combinations Against Trastuzumab-Mediated Cardiotoxicity

et al. 2021

View full text Add to dashboard Cite

show abstract

“…In animals, bone and cartilage may develop in diseased myocardium. 2 In sheep, the atria are prone to cartilage formation. 3 In mammals, particularly ungulates, the fibrous tissue of the heart may normally contain cartilage or bone.…”

Section: Discussionmentioning

confidence: 99%

Chondroid and Osseous Metaplasia of the Central Fibrous Body in Adolescent Hearts with Mutations in TNNI3 and TNNT2 genes

2020

View full text Add to dashboard Cite

The histological spectrum of the central fibrous body (CFB) of the heart, particularly in humans, is not fully characterized. Herein, we describe the presence of cartilage and bone within the CFB of 2 explanted heart specimens from patients with known mutation-driven cardiomyopathy involving the TNNI3 and TNNT2 genes, review the existing literature on the identified variants particularly TNNI3 (p.Asn185Thrfs*14) and TNNT2 (p.Arg141Trp), and provide insights into the plausible nature of such histopathological observation based on animal studies and the few reported cases in humans.

show abstract

“…64 Studies showed that TCs would be injured when normal architecture was detrimental as interstitium cartilaginous and osseous metaplasia in the later stages of myocardial infarction indicated the reaction of cell types or disease microenvironment on TCs. 65 The evidence of TCs heterocellular interaction was provided in recent studies. Inflammation factors induced TCs to provide hepatocyte growth factor to macrophages and transfer from M1 to M1/M2 state.…”

Section: F I G U R Ementioning

confidence: 94%

Single‐cell RNA sequencing reveals telocytes subsets of human lung

Dai,

Cai,

Wang

et al. 2024

Clinical and Translational Dis

View full text Add to dashboard Cite

BackgroundTelocyte (TC) is a recently defined renewed cell and its dominant intercommunication with other cells displays multiple functions in tissue homeostasis and diseases. Alveolar epithelial cells and immune cells were in the lung cancer heterogeneity, progression, and metastasis, and further associated with antitumor therapeutic strategies. However, few studies focus on the roles of TCs in lung cancer.MethodsIn this article, we used the public scRNA‐Seq data (including healthy control, chronic obstructive pulmonary disease, non–small cell lung cancer, lymph node metastases from non–small cell lung cancer, and systemic sclerosis–associated interstitial lung disease patients) to analyze the cellular dynamics in human lung and distinct types of TCs and their communication networks with the variety of cell types.ResultsSix subclusters of TCs were identified by expression of specific biological function markers, which demonstrated the diversity of TCs subsets in lung tissue. Further results showed TCs had communication with epithelial cells or immune cells subsets by the ligand–receptor interaction, including TIMP metallopeptidase inhibitor 1CD63, fibulin 1integrin subunit beta 1, vimentinCD44, macrophage migration inhibitory factorCD74, and amyloid beta precursor proteinCD74. Ligand–receptor interaction heterogeneity was revealed in lung tissue of healthy or diseases. Enhanced specific signals in ligandreceptor interaction were revealed, including integrin beta 1 and CD44 were appraised in the communication of TCs with epithelial cells, NK cells, NKT cells, CD4+ exhausted T cells, CD4+ memory/effector T cells, CD4+ naïve T cells, CD8+ exhausted T cells, CD8+ memory/effector T cells, and CD8+ naïve T cells. CD63, a marker identified in TCs exosomes was emphasized in our current analysis which is closely related to communication of TCs with other cell types.ConclusionThese results will provide us with new insight into the mechanisms of TCs‐dominated communication and promise therapy of TC exosomes in lung diseases.

show abstract

Areas of Cartilaginous and Osseous Metaplasia After Experimental Myocardial Infarction in Rats

Cited by 9 publications

References 34 publications

Therapeutic Potentials of Selected Antihypertensive Agents and Their Fixed-Dose Combinations Against Trastuzumab-Mediated Cardiotoxicity

Therapeutic Potentials of Selected Antihypertensive Agents and Their Fixed-Dose Combinations Against Trastuzumab-Mediated Cardiotoxicity

Chondroid and Osseous Metaplasia of the Central Fibrous Body in Adolescent Hearts with Mutations in TNNI3 and TNNT2 genes

Single‐cell RNA sequencing reveals telocytes subsets of human lung

Contact Info

Product

Resources

About